Testing an oral drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new oral tablet (HRS-7525) for men with advanced prostate cancer that has spread. It aims to see if the drug is safe and effective, and may offer a new treatment option for those who have not responded to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 80 years old
- Your prostate cancer has spread to other parts of the body (like bones or lymph nodes)
- You are able to perform daily activities with minimal help (ECOG score 0–1)
- You have not had other cancer treatments (like chemo, radiation, or surgery) within the past 4 weeks
- You do not have active hepatitis B or C, HIV, or other serious infections
- You do not have brain or spinal cord tumors or other severe health conditions that could interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This study tests a combination of two experimental drugs, HRS-2189 and HRS-5041, for men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The goal is to see if the combination is safe and effective in controlling tumor growth.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.